Lung Transplantation for COVID-19–related Lung Disease: Clinical Experience and Call for a Global Registry

Weder, Max; Aslam, Saima; Ison, Michael G.

doi:10.1097/tp.0000000000004327

Cited by 5 publications

(3 citation statements)

References 21 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most recently, COVID-19 as well as new viral respiratory causes of ARDS have emerged as a growing public health threat. COVID-19 related interstitial lung disease has been identified in some patients after acute illness ( 81 , 82 ). There have been a small number of case series published on LTx due to COVID-19 ( 83 ).…”

Section: Recipient Risk Factors For Development Of Pgdmentioning

confidence: 99%

Donor and recipient risk factors for the development of primary graft dysfunction following lung transplantation

Jenkins,

Verdiner,

Omar

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Primary Graft Dysfunction (PGD) is a major cause of both short-term and long-term morbidity and mortality following lung transplantation. Various donor, recipient, and technical risk factors have been previously identified as being associated with the development of PGD. Here, we present a comprehensive review of the current literature as it pertains to PGD following lung transplantation, as well as discussing current strategies to mitigate PGD and future directions. We will pay special attention to recent advances in lung transplantation such as ex-vivo lung perfusion, thoracoabdominal normothermic regional perfusion, and up-to-date literature published in the interim since the 2016 ISHLT consensus statement on PGD and the COVID-19 pandemic.

show abstract

Section: Recipient Risk Factors For Development Of Pgdmentioning

confidence: 99%

Donor and recipient risk factors for the development of primary graft dysfunction following lung transplantation

Jenkins,

Verdiner,

Omar

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Now, 364 lung transplants have been performed for COVID-19 in the United States, with over 60% of those transplants performed for COVID-19-associated ARDS. In fact, COVID-19-related diagnoses accounted for nearly 10% of the United States lung transplants performed in 2021 [ 12 ▪▪ ]. However, lung transplantation was not accepted as potentially life-saving treatment for COVID-19-associated ARDS without first discussing some concerns.…”

Section: Lung Transplantation For Acute Respiratory Distress Syndrome...mentioning

confidence: 99%

“…Further studies are needed to analyze the long-term outcomes of these transplant recipients and see how they compare with non-COVID-19-related lung transplants. In fact, Weder et al [ 12 ▪▪ ] have begun to create a global registry for COVID-19-related lung transplants to help guide clinical practices and analyze outcomes. This registry would also allow for assessment of outcomes of COVID-19 single lung transplants, which is critically important to expand an already limited donor pool of lungs.…”

Section: Future Directionsmentioning

confidence: 99%

Lung transplantation for coronavirus disease 2019 acute respiratory distress syndrome/fibrosis: silver lining of a global pandemic

Cerier

Bharat

2023

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

Purpose of reviewThe COVID-19 pandemic revolutionized the field of lung transplantation, as lung transplant is now an acceptable life-saving therapy for select patients with COVID-19-associated acute respiratory distress syndrome (ARDS), while prior to the pandemic, few transplants were performed for ARDS. This review article details the establishment of lung transplantation as a viable therapy for COVID-19-related respiratory failure, how to evaluate COVID-19 patients for lung transplant, and specific technical considerations for the operation.Recent findingsLung transplantation is a life-altering treatment for two distinct cohorts of COVID-19 patients: those with irrecoverable COVID-19-associated ARDS and those who recover from the initial COVID-19 insult but are left with chronic, debilitating post-COVID fibrosis. Both cohorts require stringent selection criteria and extensive evaluation to be listed for lung transplantation. As the first COVID-19 lung transplantation was recently performed, long-term outcomes are lacking; however, short-term outcome data of COVID-19-related lung transplants are promising.SummaryGiven the challenges and complexities associated with COVID-19-related lung transplantation, strict patient selection and evaluation are required with an experienced multidisciplinary team at a high-volume/resource center. With promising short-term outcome data, ongoing studies are needed to assess long-term outcomes of COVID-19-related lung transplants.

show abstract

The Year in Cardiothoracic Transplant Anesthesia: Selected Highlights From 2022 Part I: Lung Transplantation

Gelzinis,

Courtwright,

Whyte

et al. 2024

Journal of Cardiothoracic and Vascular Anesthesia

View full text Add to dashboard Cite

Lung Transplantation for COVID-19–related Lung Disease: Clinical Experience and Call for a Global Registry

Cited by 5 publications

References 21 publications

Donor and recipient risk factors for the development of primary graft dysfunction following lung transplantation

Donor and recipient risk factors for the development of primary graft dysfunction following lung transplantation

Lung transplantation for coronavirus disease 2019 acute respiratory distress syndrome/fibrosis: silver lining of a global pandemic

The Year in Cardiothoracic Transplant Anesthesia: Selected Highlights From 2022 Part I: Lung Transplantation

Contact Info

Product

Resources

About